Stratos Genomics, a spin-off of Seattle-based Stratos Group, has received $1.2m from existing shareholders for the development of its ultra-low-cost nucleic acid sequencing method for whole genome analysis and molecular diagnostics.
Stratos Genomics aims to establish the next gold standard of DNA sequencing with its ‘Sequencing by Expansion’ (SBX) method.
The company claims SBX is a single-molecule detection process that circumvents the limitations of competing technologies, allowing accurate, low-cost whole genome sequencing.
Stratos Genomics CEO Allan Stephan said their shareholders recognize that they are entering an exciting phase and don’t want the validation pace interrupted by external fundraising activities.